Scientists Uncover New Method to Slow Memory Decline in Alzheimer's
In a groundbreaking discovery, researchers have identified a novel approach to combat memory loss in Alzheimer's disease, a condition that affects millions worldwide. According to a recent study published in the Proceedings of the National Academy of Sciences (https://www.pnas.org/doi/10.1073/pnas.2521944123), scientists from Cold Spring Harbor Laboratory in New York have made a significant breakthrough.
The study reveals that an enzyme called PTP1B plays a crucial role in the progression of memory decline in mice with Alzheimer's. This finding opens up exciting possibilities for treatment.
The enzyme PTP1B, as discovered by Professor Nicholas Tonks in 1988, has been found to contribute to the immune cell signaling process. Researchers observed that reducing PTP1B activity enhances the brain's immune cells, known as microglia, in clearing amyloid-β (Aβ) plaques, which are protein deposits linked to Alzheimer's disease. As the disease advances, these microglia become less effective in their debris removal function.
The study further highlights the interaction between PTP1B and a protein called spleen tyrosine kinase (SYK), which regulates microglia's response to damage and their ability to clear Aβ. This discovery suggests that inhibiting PTP1B could be a promising strategy to improve microglial function and reduce Aβ plaque accumulation.
Yuxin Cen, the lead researcher, emphasized the potential impact of PTP1B inhibition, stating that it can enhance microglial function, leading to better Aβ plaque clearance.
Interestingly, PTP1B is not only implicated in Alzheimer's but also in metabolic disorders such as obesity and type 2 diabetes, which are recognized risk factors for the disease (https://www.euronews.com/health/2025/01/22/scientists-in-italy-discover-rare-genetic-mutation-that-could-be-a-cause-of-alzheimers).
The research team is now focused on developing PTP1B inhibitors for various applications. Professor Tonks envisions a combination therapy, utilizing existing approved drugs alongside PTP1B inhibitors to tackle Alzheimer's. Currently, cholinesterase inhibitors like donepezil and NMDA receptor antagonists such as memantine are used to manage the condition.
The ultimate goal, according to Tonks, is to slow down Alzheimer's progression and enhance the quality of life for patients. With over 55 million people affected by dementia globally, and Alzheimer's being the leading cause, this research offers a glimmer of hope in the fight against this devastating disease.
As Tonks, whose mother suffered from Alzheimer's, poignantly notes, this condition is a slow and gradual loss of the person. The research team's findings provide a compelling argument for further exploration and development of PTP1B-based treatments, offering a potential pathway to preserving cognitive function and slowing the progression of this debilitating disease.
